What is F2G?
F2G is a biopharmaceutical firm dedicated to pioneering new treatments for severe fungal infections that disproportionately affect vulnerable patient populations. The company's core mission revolves around a patient-first philosophy, leveraging innovative science to create effective antifungal solutions. With a commitment to tackling challenging and resistant pathogens, F2G aims to enhance therapeutic options for individuals facing dire prognoses. Their work is crucial in advancing the field of infectious disease treatment, particularly for rare and life-threatening conditions.
How much funding has F2G raised?
F2G has raised a total of $347.9M across 8 funding rounds:
Series A
$6.1M
Private Equity
$9.2M
Other Financing Round
$11.8M
Private Equity
$30M
Series C
$60M
Series D
$60.8M
Unspecified
$70M
Other Financing Round
$100M
Series A (2002): $6.1M, investors not publicly disclosed
Private Equity (2008): $9.2M, investors not publicly disclosed
Other Financing Round (2008): $11.8M supported by K Nominees, BankInvest Biomedical Venture, Merifin Capital, and Astellas Venture Management
Private Equity (2012): $30M featuring Sunstone Capital, Advent Life Sciences, Novartis BioVenture Fund, Merifin Capital, and Astellas Venture Management
Series C (2016): $60M backed by Sectoral Asset Management, Sunstone Capital, Aisling Capital, Advent Life Sciences, Novartis Venture Fund, Brace Pharma Capital, Merifin Capital, and Novo A/S
Series D (2020): $60.8M with participation from Brace Pharma Capital, Novo Holdings, Morningside Ventures, Cowen Healthcare Investments, and Advent Life Sciences
Unspecified (2022): $70M led by Novo Holdings, Advent Life Sciences, Sofinnova Partners, Morningside Venture Capital, Cowen Healthcare Investments, and Forbion
Other Financing Round (2024): $100M supported by Novo Holdings, Advent Life Sciences, ICG, Sofinnova Partners, and The AMR Action Fund
Key Investors in F2G
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focused on investing in life sciences and healthcare innovations.
Advent Life Sciences
Advent Life Sciences is a leading trans-Atlantic venture capital firm specializing in early and mid-stage investments in innovative life sciences businesses, aiming to develop first-in-class medicines.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability, with a focus on building transformative innovations from seed to later stages.
What's next for F2G?
The substantial enterprise-level backing F2G has garnered, culminating in its total funding of $347.9M, positions the company for significant growth and operational expansion. The recent strategic investment of $100M is likely to fuel further research and development, potentially enabling F2G to advance its pipeline candidates through clinical trials and towards market approval. This capital will also support the company's efforts to scale its operations and solidify its market presence in the specialized field of antifungal therapeutics, aiming to address critical unmet medical needs.
See full F2G company page
